2022
DOI: 10.3390/cancers14143318
|View full text |Cite
|
Sign up to set email alerts
|

The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer

Abstract: Recurrent epithelial ovarian cancer (EOC) coincident with chemotherapy resistance remains the main contributor to patient mortality. There is an ongoing investigation to enhance patient progression-free and overall survival with novel chemotherapeutic delivery, such as the utilization of antiangiogenic medications, PARP inhibitors, or immune modulators. Our preclinical studies highlight a novel tool to combat chemotherapy-resistant human EOC. Glycosylated antitumor ether lipids (GAELs) are synthetic glycerolip… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 99 publications
0
1
0
Order By: Relevance
“…A similar double glycosylation but with mono-amino glycoside was also reported by Arthur and Schweizer [ 258 ]. The singularity of the biological action of this class of compounds (amino glycoside ether lipids) that kill cancer cells by methuosis (apoptosis independent pathway) was recently reviewed [ 259 ].…”
Section: Reviewmentioning
confidence: 99%
“…A similar double glycosylation but with mono-amino glycoside was also reported by Arthur and Schweizer [ 258 ]. The singularity of the biological action of this class of compounds (amino glycoside ether lipids) that kill cancer cells by methuosis (apoptosis independent pathway) was recently reviewed [ 259 ].…”
Section: Reviewmentioning
confidence: 99%